These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22502761)

  • 1. Should routine screening for celiac disease be considered before starting interferon/ribavirin treatment in patients affected by chronic hepatitis C or not?
    Nejad MR; Alavian SM
    Bratisl Lek Listy; 2012; 113(4):251. PubMed ID: 22502761
    [No Abstract]   [Full Text] [Related]  

  • 2. Celiac disease manifested during the treatment of chronic hepatitis C by pegylated alpha interferon and ribavirin.
    Gombosova L; Jarcuska P; Benova B; Benicky M; Lazurova I
    Bratisl Lek Listy; 2011; 112(6):360-2. PubMed ID: 21692415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Martins EV; Gaburri AK
    Arq Gastroenterol; 2004; 41(2):132-3. PubMed ID: 15543388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    Adinolfi LE; Durante Mangoni E; Andreana A
    Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic viral hepatitis, interferon, diabetes mellitus, and celiac disease.
    Narváez I; Pérez B; del Mar Alcalde M; Jiménez C; Soria A
    Am J Gastroenterol; 2003 Oct; 98(10):2336-7. PubMed ID: 14572601
    [No Abstract]   [Full Text] [Related]  

  • 6. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C.
    Horev A; Halevy S
    Isr Med Assoc J; 2009 Dec; 11(12):760-1. PubMed ID: 20166347
    [No Abstract]   [Full Text] [Related]  

  • 7. Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
    Lin J; Lott JP; Amorosa VK; Kovarik CL
    J Am Acad Dermatol; 2009 May; 60(5):882-3. PubMed ID: 19389538
    [No Abstract]   [Full Text] [Related]  

  • 8. Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection.
    Adişen E; Dizbay M; Hizel K; Ilter N
    Indian J Dermatol Venereol Leprol; 2008; 74(1):60-2. PubMed ID: 18187830
    [No Abstract]   [Full Text] [Related]  

  • 9. Peginterferon and ribavirin for hepatitis C.
    Ben Salem C; Hmouda H; Bouraoui K
    N Engl J Med; 2007 Mar; 356(12):1270; author reply 1271. PubMed ID: 17380578
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: "Erythema Annulare Centrifugum due to Pegylated Interferon-α-2a plus Ribavirin Combination Therapy in a Patient with Chronic Hepatitis C Virus Infection".
    Naccarato M; Yoong D; Solomon R; Ostrowski M
    J Cutan Med Surg; 2015; 19(1):10. PubMed ID: 25775656
    [No Abstract]   [Full Text] [Related]  

  • 11. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
    Atug O; Akin H; Yilmaz Y; Sari M; Tozun N
    J Gastrointestin Liver Dis; 2009 Jun; 18(2):256. PubMed ID: 19565068
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.
    Sprenger R; Sagmeister M; Offner F
    Gut; 2005 Mar; 54(3):438-9; author reply 439. PubMed ID: 15710996
    [No Abstract]   [Full Text] [Related]  

  • 13. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
    Musialik J; Petelenz M; Błoñska-Fajfrowska B; Hartleb M
    Eur J Gastroenterol Hepatol; 2009 May; 21(5):593-4. PubMed ID: 19194303
    [No Abstract]   [Full Text] [Related]  

  • 14. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Iwasaki Y; Ikeda F; Yamamoto K
    Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
    [No Abstract]   [Full Text] [Related]  

  • 15. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anterior uveitis in a patient treated with pegylated interferon and ribavirin].
    Carneros Martín JA; Fuentes Coronel A; Alvarez Delgado A; González San Martín F
    Med Clin (Barc); 2003 Mar; 120(9):359. PubMed ID: 12646118
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
    Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
    Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin.
    Choy-Shan A; Berezovskaya S; Zinn A; Sedlis SP; Bini EJ
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1438-40. PubMed ID: 19907230
    [No Abstract]   [Full Text] [Related]  

  • 20. What caused this lingual hyperpigmentation in a patient with chronic hepatitis C?
    Radha Krishna Y; Itha S
    Liver Int; 2010 Mar; 30(3):416. PubMed ID: 19422481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.